ArticleCancer medicine2026
A Novel Modified Bu/Vp16/cy/Flu/Ara-C Conditioning Regimen Enhances Outcomes for High-Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CAR-T versus allogeneic transplantation as consolidation for B-cell acute lymphoblastic leukemia in remission: a propensity-score matched study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeAllogeneic hematopoietic stem cell transplantation (allo-HSCT) effectively treats high-risk acute lymphoblastic leukemia (ALL), yet challenges persist due to post-transplant relapse and conditioning regimen toxicities. The determination of an appropriate preconditioning regimen is critical to improving patient outcomes. In our transplant center, we have modified the traditional busulfan (Bu)/cyclophosphamide (Cy)/etoposide (Vp16) protocol by adding fludarabine (Flu) and cytarabine (Ara-C), while reducing the dosage of Cy. This novel modification seeks to enhance transplantation outcomes for ALL patients.
methodsThis study retrospectively collected clinical data from 88 high-risk ALL patients who received transplantation from June 2018 to December 2023. Among these patients, 40 received the novel modified Bu/Cy/Vp16/Flu/Ara-C conditioning protocol, while 48 received the traditional Bu/Cy/Vp16 regimen and served as a control group.
resultsThis study demonstrated a notably reduced incidence of cardiac toxicity in patients treated with the modified Bu/Cy/Vp16/Flu/Ara-C conditioning compared to those on the traditional Bu/Cy/Vp16 regimen. Furthermore, other types of conditioning-related toxicities were within acceptable limits in the modified regimen group. Regarding efficacy, the Bu/Cy/Vp16/Flu/Ara-C protocol significantly reduced the cumulative two-year relapse rate in high-risk ALL patients compared to the Bu/Cy/Vp16 scheme (38.7% (20.9%-52.5%) vs. 11.8% (0.2%-22.1%), p = 0.017). The modified regimen showed significant improvements in 2-year overall survival at 71.6% (57.1%-89.6%) compared to 50.6% (38%-67.3%) (p = 0.048), and in two-year disease-free survival at 66.7% (51.9%-85.6%) compared to 45.3% (33.1%-62.1%) (p = 0.015). Transplant-related mortality was comparable between the two groups. A subgroup analysis based on disease status (CR1 and ≥ CR2) revealed that high-risk ALL patients on the modified regimen had lower relapse rates and significantly better OS and DFS than those on the Bu/Cy/Vp16 scheme.
conclusionsThe novel modified Bu/Cy/Vp16/Flu/Ara-C conditioning significantly enhances the prognosis of high-risk ALL patients receiving transplantation, especially those in CR1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.